<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04388293</url>
  </required_header>
  <id_info>
    <org_study_id>H19-02490</org_study_id>
    <nct_id>NCT04388293</nct_id>
  </id_info>
  <brief_title>Using Antibiotics Wisely - An Antimicrobial Stewardship Program</brief_title>
  <official_title>Using Antibiotics Wisely - Development of National Neonatal Intensive Care Unit-specific ASP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Memorial University of Newfoundland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Eastern Ontario</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Université de Montréal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are significant variations in antimicrobial consumption across Canadian Neonatal
      Intensive Care Units (NICUs). Inappropriate and overuse of antibiotics can result in
      antimicrobial resistance and adverse outcomes among vulnerable neonatal populations. There
      are limited data on broad-spectrum antimicrobial use, multi-drug resistant organisms (MDRO)
      prevalence, and effective NICU-specific antimicrobial stewardship strategies. The aim of this
      study is to develop and implement NICU-specific antimicrobial stewardship strategies at both
      national and individual unit levels to promote optimal antimicrobial use and decrease the
      incidence of MDROs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose: The investigators aim to develop and implement NICU-specific Antimicrobial
      Stewardship Program (ASP) strategies at both national and individual unit levels to promote
      optimal antimicrobial use and decrease the incidence of multi-drug resistant organisms (MDRO)
      in Canada.

      Hypothesis: The investigators expect to find:

        -  Significant national variation in broad-spectrum antimicrobial use, which will not be
           correlated with rates of sepsis. High antimicrobial consumption rates may be associated
           with limited existing ASP resources and increased neonatal morbidity related to
           inflammatory cascades.

        -  Significant national variation in the prevalence of MDROs across NICUs.

        -  Differences in empirical antimicrobial regimens may be associated with MDRO prevalence,
           and the variation in antimicrobial use may explain some variation in neonatal morbidity.

      Study Population and Sample Size: The study population will include very-low-birth-weight
      (VLBW) infants (i.e., the group of infants neonates with the highest risk of infections
      within NICUs) admitted to participating tertiary NICUs in Canada.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Days of therapy/1000 patient-day of each category of antimicrobial consumption</measure>
    <time_frame>2020-2024</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of multi-drug resistant organisms in infections among very-low-birth-weight neonates during their NICU stay</measure>
    <time_frame>2020-2024</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Association between multi-drug resistant organisms, broad-spectrum antimicrobial use, neonatal outcomes and existing Antimicrobial Stewardship Programs &amp; screening policies.</measure>
    <time_frame>2020-2024</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Multi-Drug Resistant Organisms</condition>
  <condition>Late-Onset Sepsis, Neonatal</condition>
  <condition>Antimicrobial Resistance</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exposure of interest</intervention_name>
    <description>Very Low Birth Weight infants admitted to tertiary NICUs in Canada.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will include all VLBW infants admitted to participating tertiary NICUs
        in Canada. The investigators will exclude infants with major congenital anomalies to avoid
        confounding factors when analyzing the impact of antimicrobial use and MDRO on neonatal
        outcomes. All VLBW infants will be included in the primary MDRO prevalence analysis. The
        investigators expect ~2000 VLBW infants with culture-proven infections in the study period.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Very-low-birth-weight infants admitted to participating tertiary NICUs in Canada.

        Exclusion Criteria:

          -  infants with major congenital anomalies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Weeks</minimum_age>
    <maximum_age>44 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Joseph Ting, Clin Associate Prof</last_name>
    <phone>6048752000</phone>
    <phone_ext>5380</phone_ext>
    <email>JTing2-02@cw.bc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Esther Alonso, Phd</last_name>
    <phone>6048752000</phone>
    <phone_ext>7408</phone_ext>
    <email>esther.alonsoprieto@cw.bc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>BC Women's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 10, 2020</study_first_submitted>
  <study_first_submitted_qc>May 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2020</study_first_posted>
  <last_update_submitted>May 13, 2020</last_update_submitted>
  <last_update_submitted_qc>May 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Joseph Ting</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Antimicrobial Stewardship</keyword>
  <keyword>Prematurity</keyword>
  <keyword>Neonate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neonatal Sepsis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

